Reva Medical (ASX:RVA) said today that it closed the 2nd tranche of its $34.6 million financing round. The company issued $47.1 million convertible notes, 2,119,500 options for the purchase of common stock and repurchased $12.5 million of its common stock from 1 unnamed investor.
The San Diego, Calif.-based company’s 1st commercial product is its Fantom sirolimus-eluting bioresorbable coronary scaffold. The device won CE Mark approval in the European Union in April.
Get the full story at our sister site, Drug Delivery Business News.
The post Reva closes $35m financing round appeared first on MassDevice.
from MassDevice http://ift.tt/2ryIG81
Cap comentari:
Publica un comentari a l'entrada